CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy
- Conditions
- Oral Complications of Radiation TherapyPainWeight ChangesHead and Neck Cancer
- Interventions
- Other: placeboDietary Supplement: Lactobacillus brevis CD2 lozenge
- Registration Number
- NCT01545687
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Brief Summary
RATIONALE: Lactobacillus bevis CD2 lozenge may help prevent symptoms of mucositis, or mouth sores, in patients receiving radiation therapy and chemotherapy. This therapy may improve the quality of life of patients with head and neck cancer.
PURPOSE: This phase III trial studies how well Lactobacillus bevis CD2 lozenge prevents oral mucositis in patients with head and neck cancer who are being treated with cisplatin and radiation therapy. These results will be compared to results in patients using placebo lozenges.
- Detailed Description
OBJECTIVES:
Primary
* To determine whether Lactobacillus brevis CD2 lozenges are effective in reducing oral mucositis (OM)-related pain in patients undergoing chemoradiotherapy (CRT) for head and neck squamous cell carcinoma, as measured by the area under the curve (AUC) of Mouth and Throat Soreness (MTS) score (Oral Mucositis Daily Questionnaire \[OMDQ\] question 2) measured daily during CRT and daily for 4 weeks after completion of CRT.
Secondary
* To assess whether L. brevis CD2 lozenges reduce OM as assessed by the provider using the WHO OM scale, Oral Mucositis Assessment Scale (OMAS), and Common Terminology Criteria Adverse Events (CTCAE).
* To assess whether L. brevis CD2 lozenges reduce the impact of OM on the ability to swallow, drink, eat, talk, and sleep, as assessed by the MTS-Activity Limitations (MTS-AL).
* To assess whether L. brevis CD2 lozenges improve quality of life, as assessed by the Functional Assessment of Cancer Therapy - Head and Neck (FACT-HN).
* To assess whether L. brevis CD2 lozenges reduce opioid requirements.
* To assess whether L. brevis CD2 lozenges improve radiotherapy compliance.
* To assess whether L. brevis CD2 lozenges reduce weight loss and the need for a feeding tube.
* To assess whether L. brevis CD2 lozenges affect disease-free survival (DFS) at 12 months after treatment.
* To evaluate the effect of L. brevis CD2 lozenges on salivary biomarkers, including metabonomic and inflammatory markers, as measured at baseline, week 3 of CRT, and during the last week of CRT. (exploratory)
OUTLINE: This is a multicenter, randomized, placebo-controlled, double-blind study. Patients are stratified according to primary disease site (oral cavity/oropharynx vs nasopharynx vs hypopharynx/larynx), context of chemoradiotherapy (CRT) (definitive vs post-operative), cisplatin schedule (every 3 weeks \[100 mg/m\^2\] vs every week \[30-40 mg/m\^2\]), and use of intensity-modulated radiotherapy (IMRT) (yes vs no). Patients are randomized to 1 of 2 treatment regimens.
* Arm I: Patients dissolve in mouth 1 lozenge of Lactobacillus brevis CD2 every 2-3 hours (total of 6 per day) daily during CRT (comprising cisplatin and radiotherapy \[RT\]) and for 4 weeks after, including weekends.
* Arm II: Patients dissolve in mouth 1 lozenge of placebo every 2-3 hours (total of 6 per day) daily during CRT and for 4 weeks after, including weekends.
Patients complete questionnaires about their quality of life and pain at baseline and daily during study treatment.
Saliva is collected from some patients before starting RT, during week 3 of RT, and during the last week of RT for NMR-spectroscopic metabolomic analysis and future cytokine analysis.
After completion of study treatment, patients are followed up at 12 months.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm II placebo Patients dissolve in mouth 1 lozenge of placebo every 2-3 hours (total of 6 per day) daily during CRT and for 4 weeks after, including weekends. Arm I Lactobacillus brevis CD2 lozenge Patients dissolve in mouth 1 lozenge of Lactobacillus bevis CD2 every 2-3 hours (total of 6 per day) daily during CRT (comprising cisplatin and radiotherapy \[RT\]) and for 4 weeks after, including weekends.
- Primary Outcome Measures
Name Time Method The AUC of the MTS score Up to 12 months
- Secondary Outcome Measures
Name Time Method OM measured by WHO OM scale, OMAS and CTCAE weekly during CRT Up to 12 months Opioid requirement (frequency, morphine equivalent dose) as measured by daily OMDQ Up to 12 months Impact of OM on the ability to swallow, drink, eat, talk, and sleep, as assessed by the MTS-AL Up to 12 months Quality of life as assessed by the FACT-HN Up to 12 months DFS at 12 months after treatment at 12 months